Utilization and expense of adjuvant cancer therapies following radical prostatectomy
Stephen B. Williams(Cedars-Sinai Medical Center), Jim C. Hu(Presbyterian Hospital), Paul L. Nguyen(Beth Israel Deaconess Medical Center), Toni K. Choueiri(Harvard University), Xiangmei Gu(Brigham and Women's Hospital), Stuart R. Lipsitz(Brigham and Women's Hospital)
Cited by 31
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k